Trials / Terminated
TerminatedNCT00180830
Glivec Phase II Pediatric Study
Open Label, Pilot Phase II Study of Glivec in Children and Adolescents With Life Threatening Diseases Known to Be Associated With One or More Glivec-Sensitive Tyrosine Kinases
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (planned)
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
- Sex
- All
- Age
- 6 Months – 21 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Glivec is effective, in children, adolescents and young adults, in the treatment of malignant disease in which evidence suggests a potential pathogenic role of one or more of the tyrosine kinases known to be inhibited by Glivec.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glivec | |
| DRUG | Gleevec |
Timeline
- Start date
- 2003-12-01
- First posted
- 2005-09-16
- Last updated
- 2006-09-11
Locations
3 sites across 3 countries: France, Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT00180830. Inclusion in this directory is not an endorsement.